The estimated Net Worth of Alan Lewis is at least 4.82 百万$ dollars as of 28 August 2018. Alan Lewis owns over 7,500 units of Biomarin Pharmaceutical stock worth over 2,429,795$ and over the last 19 years he sold BMRN stock worth over 1,923,178$. In addition, he makes 465,520$ as Independent Director at Biomarin Pharmaceutical.
Sign up
Alan Lewis BMRN stock SEC Form 4 insiders trading
Alan has made over 8 trades of the Biomarin Pharmaceutical stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 7,500 units of BMRN stock worth 107,925$ on 28 August 2018.
The largest trade he's ever made was selling 40,000 units of Biomarin Pharmaceutical stock on 6 August 2012 worth over 1,502,800$. On average, Alan trades about 4,663 units every 126 days since 2005. As of 28 August 2018 he still owns at least 28,660 units of Biomarin Pharmaceutical stock.
You can see the complete history of Alan Lewis stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alan Lewis biography
Dr. Alan James Lewis, Ph.D., serves as an Independent Director of Biomarin Pharmaceutical Inc. Dr. Lewis joined our Board in June 2005 and serves as the Chair of the Science and Technology Committee. Since March 2015, Dr. Lewis has served as Chief Executive Officer of DiaVacs, Inc., a private biotechnology company, where he also serves as Director. From October 2012 to March 2014, Dr. Lewis served as Chief Executive Officer and Director of Medistem, Inc. (Medistem), a public biotechnology company. From November 2011 to October 2012, he served as a consultant to Medistem and to the California Institute for Regenerative Medicine. From July 2010 to November 2011, Dr. Lewis served as President, Chief Executive Officer and Director of Ambit Biosciences, a private biotechnology company. From January 2009 to June 2010, Dr. Lewis served as President and Chief Executive Officer of The Juvenile Diabetes Research Foundation. From February 2006 until December 2008, Dr. Lewis was the President and Chief Executive Officer of Novocell, Inc., a private regenerative disease biotechnology company focused on stem cell therapy. Prior to joining Novocell Inc., starting in 2000, he was President of Celgene Signal Research, a wholly-owned subsidiary of the Celgene Corporation, a pharmaceutical company. From February 1994 to August 2000, he was the President and Chief Executive Officer of Signal Pharmaceuticals, Inc., where he guided the company to its successful acquisition by Celgene Corporation. From 1979 to 1994, Dr. Lewis held a number of positions at Wyeth-Ayerst Research and its predecessor, Wyeth Laboratories, Inc., including Vice President of Research at Wyeth-Ayerst Research. Dr. Lewis has published over 120 full manuscripts and has written and edited seven books. Dr. Lewis was a Research Associate at Yale University from 1972 to 1973. In December 2015, Dr. Lewis was appointed to the board of Assembly Biosciences, Inc., a public biotechnology company.
What is the salary of Alan Lewis?
As the Independent Director of Biomarin Pharmaceutical, the total compensation of Alan Lewis at Biomarin Pharmaceutical is 465,520$. There are 12 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of 18,405,900$.
How old is Alan Lewis?
Alan Lewis is 74, he's been the Independent Director of Biomarin Pharmaceutical since 2005. There are no older and 22 younger executives at Biomarin Pharmaceutical.
What's Alan Lewis's mailing address?
Alan's mailing address filed with the SEC is C/O ASSEMBLY BIOSCIENCES, INC., 331 OYSTER POINT BLVD, FOURTH FLOOR, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Biomarin Pharmaceutical
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over 153,109,113$ worth of Biomarin Pharmaceutical stock and bought 151,118 units worth 2,557,509$ . The most active insiders traders include Jean Jacques Bienaime、Mark J Enyedy、Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of 912,996$. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth 64,260$.
What does Biomarin Pharmaceutical do?
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
What does Biomarin Pharmaceutical's logo look like?
Complete history of Alan Lewis stock trades at Assembly Biosciences Inc、Biomarin Pharmaceutical
Biomarin Pharmaceutical executives and stock owners
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include:
-
Jean-Jacques Bienaime,
Chairman of the Board, Chief Executive Officer -
Henry Fuchs,
President - Worldwide Research & Development -
Jeff Ajer,
Executive Vice President, Chief Commercial Officer -
Jean-Jacques Bienaime M.B.A., MBA,
Chairman & CEO -
G. Eric Davis,
Executive Vice President, General Counsel, Secretary -
Dr. Henry J. Fuchs,
Pres of Worldwide R&D -
Dr. C. Greg Guyer Ph.D.,
CTO and Exec. VP of Global Manufacturing & Technical Operations -
Jeffrey Robert Ajer,
Exec. VP & Chief Commercial Officer -
Brian R. Mueller,
Exec. VP of Fin. & CFO -
Richard Meier,
Lead Independent Director -
Elaine Heron,
Independent Director -
Robert Hombach,
Independent Director -
Alan Lewis,
Independent Director -
Michael Grey,
Independent Director -
V. Bryan Lawlis,
Independent Director -
David Pyott,
Independent Director -
Dennis Slamon,
Independent Director -
Willard Dere,
Independent Director -
Elizabeth Anderson,
Independent Director -
Lon Cardon,
Chief Scientific Strategy Officer -
Andrea Acosta,
Chief Accounting Officer, Group Vice President -
C. Greg Guyer,
Chief Technical Officer, Executive Vice President of Global Manufacturing, Technical Operations -
Brian Mueller,
Chief Financial Officer, Executive Vice President -
Dr. Brinda Balakrishnan M.D., Ph.D.,
Group VP of Corp. & Bus. Devel. -
Philip Lo Scalzo,
Sr. VP & Chief Compliance Officer -
George Eric Davis,
Exec. VP, Gen. Counsel & Sec. -
Traci McCarty,
VP of Investor Relations -
Andrea L. Acosta,
Group VP & Chief Accounting Officer -
Daniel K Spiegelman,
EVP, Chief Financial Officer -
Athena Countouriotis,
Director -
Mark J Enyedy,
Director -
Barbara W. Bodem,
Director -
Robert Baffi,
President, Global Mfg/Tech Ops -
Cristin Hubbard,
EVP, Chief Commercial Officer -
Kathryn E Falberg,
Director -
William D Young,
Director -
Pierre Lapalme,
Director -
Jeffrey Landau,
Sr. Vice President, Admin. -
Gwynn Williams,
Director -
Steve Aselage,
SVP, Global Commercial Ops -
Christopher M Starr,
Sr. VP, Scientific Operations -
Franz L Cristiani,
Director -
Jeffrey H Cooper,
Chief Financial Officer -
Joseph Iii Klein,
Director -
Emil D Kakkis,
SVP, Business Operations -
Kenneth Bate,
Director -
Mark Wood,
VP, Human Resources -
John Urquhart,
Director -
Erich Sager,
Director -
Stuart J Swiedler,
SVP, Clinical Affairs -
Fredric D Price,
Chief Executive Officer -
Vijay B Samant,
Director -
Maykin Ho,
Director -
Mark J Alles,
Director -
Erin Burkhart,
GVP, Chief Accounting Officer -
Alexander Hardy,
Chief Executive Officer